Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to ...

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, ...

Pfizer, the U.S.-based pharmaceutical giant, revealed its second-quarter financial results on Tuesday, showcasing a robust 10 ...

Pfizer Inc displayed a robust performance in its Q2 2025 earnings call, with significant strides in revenue and research ...

Moreover, data on Tuesday showed that the U.S. trade deficit narrowed by more than anticipated in June, reflecting a dip in ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Central to Nxera’s pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from ...

The Department of Health and Human Services will cancel contracts and pull funding for some vaccines that are being developed ...

Q2 2025 Earnings Conference Call August 5, 2025 10:00 AM ETCompany ParticipantsAamir Malik - Corporate ParticipantAlbert Bourla ...